目的 基于加權(quán)TOPSIS法構(gòu)建脯氨酸恒格列凈藥物利用評(píng)價(jià)（DUE）標(biāo)準(zhǔn)，為臨床合理性用藥提供科學(xué)依據(jù)。方法 以脯氨酸恒格列凈說明書為基礎(chǔ)，結(jié)合相關(guān)指南和專家共識(shí)建立脯氨酸恒格列凈DUE標(biāo)準(zhǔn)；并運(yùn)用加權(quán)TOPSIS法對(duì)廣東醫(yī)科大學(xué)附屬醫(yī)院2023年10月—2024年12月使用了脯氨酸恒格列凈的住院患者病例進(jìn)行DUE，并根據(jù)評(píng)價(jià)結(jié)果進(jìn)行分析與評(píng)價(jià)。結(jié)果 7項(xiàng)指標(biāo)對(duì)應(yīng)的相對(duì)權(quán)重分別為20.24%、19.05%、14.76%、15.95%、7.86%、10.48%、11.67%；C_i≥0.8有312例（60.47%），0.6≤C_i＜0.8有148例（28.68%），C_i＜0.6有56例（10.85%）；56例不合理用藥主要集中在觀察與監(jiān)測(cè)、不良反應(yīng)、特殊人群、藥物相互作用4個(gè)方面。結(jié)論 加權(quán)TOPSIS法能夠?yàn)榕R床藥師提供有針對(duì)性的藥學(xué)干預(yù)措施，本院脯氨酸恒格列凈的使用情況整體良好，但仍需針對(duì)存在的問題加強(qiáng)監(jiān)管，以優(yōu)化臨床用藥實(shí)踐。

Objective Based on the weighted TOPSIS method, the drug utilization evaluation (DUE) criteria of henagliflozin proline was established to provide scientific basis for clinical rational drug use. Methods The DUE of henagliflozin proline were established through a combination of its instructions, pertinent guidelines, and expert consensuses. The weighted TOPSIS method was utilized to assess the DUE of hospitalized patients who were prescribed henagliflozin proline at Guangdong Medical University Affiliated Hospital between October 2023 and December 2024. Subsequently, the findings were subjected to analysis and evaluation. Results Relative weights of the seven indicators were as follows: 20.24%, 19.05%, 14.76%, 15.95%, 7.86%, 10.48%, and 11.67%, respectively. Among the 312 cases with C_i≥0.8 (60.47%), there were 148 cases (28.68%) with 0.6≤C_i＜0.8, and 56 cases (10.85%) with C_i＜0.6. The primary areas of irrational drug use identified were observation and monitoring, adverse reaction, special populations and drug interactions. Conclusion Weighted TOPSIS method can offer precise pharmaceutical interventions for clinical pharmacists. While the overall utilization of henagliflozin proline in our hospital is satisfactory, there is a need to enhance monitoring of current issues to enhance the optimization of clinical medication practices.

R977

廣東省基礎(chǔ)與應(yīng)用基礎(chǔ)研究基金課題（2023A1515110955）；廣東省醫(yī)學(xué)會(huì)臨床科研專項(xiàng)基金項(xiàng)目（2024HY-A1002）；北京醫(yī)學(xué)獎(jiǎng)勵(lì)基金課題（YXJL-2023-0314-0210）